Aim2Cerv

Aim2Cerv is a phase 3 clinical study for an investigational immunotherapy drug with the potential to treat high-risk, locally advanced cervical cancer. Artcraft Health developed the global trial identity, recruitment materials, and educational support for both sites and patients. Among other components, the study materials included a guide to the study and informed consent for sites to share with patients, a patient brochure, and a video featuring two prominent KOLs and a patient advocate. The video helped educate and recruit women to be their own advocates and inquire about the research study.